Leading Edge Predictors for Drug Discovery

CSLogWS Home

CSLogD Home

CSLogP Home

CSBBB Home

CSPB Home

CSGenoTox Home

CSHIA Home

CSBBB 

     ...Dataset Profile

Dataset Used in the CSBBB  Modeling Process

All calculated logBB values were generated using CSBBB, and were based on the 2D drug structure. Blood-brain barrier partitioning data came from 11 sources (1-11), where the testing protocol used an IV mode to administer compounds to rats. 109 neutral compounds were selected of which 99% were drug-like in terms of Lipinski’s rule of fives. 

( see CSpKa Dataset Profile for an explination of the, "Rule of Fives" )


(1) R. C. Young (1988) J. Med. Chem. 31, 656;  (2) M. H. Abraham (1994) J. Pharm. Sci. 83, 1257;  (3) T. Salminem (1997) J. Pharm. Biomed. Anal. 15, 469;  (4) D. E. Clark (1999) J. Pharm. Sci. 83, 815;  (5) J. M. Luco (1999) J. Chem. Inf. Comput. Sci. 39, 396;  (6) M. Yazdanian (1998) J Pharm. Sci. 87, 306;  (7) N. H. Grieg (1995) in New Concepts of a Blood Brain Barier, Plenum: New York, 251;  (8) J. H. Lin (1994) J. Pharmacol. Exptl. Therapeut. 271, 1217;  (9) F. Lombardo  (1996)J. Med. Chem. 39, 4750;  (10) K. Van Belle (1995) J. Pharmacol. Exptl. Therapeut.272, 1217;  (11) J. A. D. Calder (1994) Drug Design Discovery11, 259.

CSBBB  Compound Profile

A compound profile of the CSBBB training set is given below. 


CSBBB validation results on these compounds can be found at CSBBB  Experimental.

CSBBB  Representative Compounds

Follow the link below to a set of 23 representative compounds of the 109 used in the development of CSBBB.  Each structure is given along with a comparison of known experimental values and their predicted logBB.

Go to: CSBBB  Compounds

Back to: CSBBB  Home Page

search
links
user login
contact us

To contact us:

Phone: 978-501-0633

Fax: 781-275-5197

Email:  sales@chemsilico.com

Copyright © 2003 ChemSilico LLC All Rights Reserved

Terms and Conditions of Use | Privacy Policy

ChemSilico is a registered trademark of ChemSilico LLC, Tewksbury, MA 01876